Current Report Filing (8-k)
March 19 2018 - 6:45AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 19, 2018
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other
|
|
(Commission
|
|
(I.R.S.
Employer
|
jurisdiction
of incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
1880
Century Park East, Suite 1000
|
|
|
|
Los
Angeles, California
|
|
90067
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
2.02. Results of Operation and Financial Condition
On
March 19, 2018, Ritter Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results
for the three-month period and full year ending December 31, 2017, entitled “Ritter Pharmaceuticals Reports Fourth Quarter
and Full Year 2017 Financial Results and Provides Business Update” (the “Press Release”). A copy of the Press
Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The
information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of
Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18.
Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing
under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such
filings.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RITTER PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
Name:
|
Michael
D. Step
|
|
Title:
|
Chief
Executive Officer
|
Date:
March 19, 2018
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024